Elanco Receives Positive CHMP Recommendation for Bexagliflozin (Bexatil), a Novel Treatment for Feline Diabetes, in Europe
SGLT2 Inhibitor Enters the European Animal Health Market
Elanco Animal Health (ELAN) has received a positive opinion from the Committee for Medicinal Products for Veterinary Use (CVMP) of the European Medicines Agency (EMA) for Bexatil (bexagliflozin), its treatment for feline diabetes. Bexatil is an oral sodium-glucose cotransporter-2 (SGLT2) inhibitor that helps manage hyperglycemia in cats and offers a potential alternative to existing insulin injections. The decision was officially adopted during the CVMP meeting held from July 14 to 16, 2026, and represents a crucial step towards final approval by the European Commission (EC). Elanco has already successfully launched Bexacat in the United States in December 2022, following FDA approval, and this recommendation paves the way for its commercialization in the European market.
Innovative Shift in Feline Diabetes Treatment
Feline diabetes is a chronic condition that traditionally requires twice-daily insulin injections, posing challenges for pet owners in terms of convenience and adherence. Bexatil, however, is developed as a once-daily oral tablet, which is expected to significantly reduce the psychological and physical burden on pet owners. Its mechanism of action, inhibiting glucose reabsorption in the kidneys and promoting glucose excretion in the urine, is transforming the paradigm of feline diabetes treatment from injections to oral administration. However, its use is limited to cats that are not insulin-dependent or suffering from diabetic ketoacidosis (DKA), making thorough veterinary screening and monitoring essential.
Fierce Competition in the $2.2 Billion Companion Animal Health Market
The global market for companion animal diabetes management is estimated at $2.2 billion in 2025 and is growing rapidly at an annual rate of 6-9%, driven by increasing awareness of pet health and rising obesity rates. The current leading competitor in the market is Senvelgo (belagliflozin), an oral SGLT2 inhibitor developed by Boehringer Ingelheim and approved in Europe in November 2023. Elanco's Bexatil aims to capture a significant share of the rapidly growing feline-specific drug market by targeting pet owners who prefer oral tablets, thereby challenging Senvelgo's dominance. This competition between the two global pharmaceutical companies is expected to drive innovation and raise the overall technological level and market value of the companion animal healthcare industry.
Commercial Growth Momentum Beyond Regulatory Approval
The CVMP's positive recommendation is expected to lead to final marketing authorization from the European Commission (EC) within approximately 67 days, signaling a strong positive outlook for Elanco's European revenue diversification. Elanco acquired the license for animal use of bexagliflozin from Increvet, a subsidiary of TheracosBio, the company that developed the drug, with specific terms of the agreement remaining confidential. Following its successful launch in the United States, the introduction of Bexatil through veterinary distribution networks across Europe is expected to significantly contribute to improving Elanco's profitability in the companion animal segment. Due to the nature of chronic disease treatments, long-term prescription rates are expected to be high, making it a valuable asset for the company's stable cash flow.
The positive CHMP recommendation for Bexatil in Europe, following its FDA approval in the United States, secures Elanco's (ELAN) entry into the vast European companion animal market, significantly strengthening its portfolio in the companion animal segment. This positions Elanco to form a duopoly with Boehringer Ingelheim's Senvelgo in the global companion animal diabetes market, estimated at $2.2 billion in 2025. Veterinary researchers and clinicians believe that the shift from twice-daily insulin injections to once-daily oral tablets will dramatically improve medication adherence in feline patients and reduce monitoring costs. While increased marketing costs are expected in the short term due to the European market launch, in the medium to long term, the high patient retention characteristic of chronic diseases is expected to drive both revenue growth and improved profitability for Elanco.